The Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke

This observational study aims to investigate the impact of GGCX gene mutations and GGCX levels on stroke prognosis in patients with ischemic stroke, as well as their correlation. The main issues are:

What is the relationship and potential mechanism between GGCX gene mutations and their expression levels and the composite prognosis of recurrence, death, and bleeding events in patients with ischemic stroke? Collect blood samples from enrolled ischemic stroke patients for genetic testing, and conduct follow-up visits at 3, 6, and 12 months after discharge to evaluate clinical prognosis outcomes. This will answer questions about the relationship and mechanism between GGCX gene and patient prognosis.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Acute Ischemic Stroke Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Ischemic Stroke Nervous System Diseases Stroke Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Peking University Aerospace Center Hospital

Beijing, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion Criteria

(1) Inclusion Criteria for Acute Ischemic Stroke Patients:

Aged between 18 and 85 years.
Diagnosed with ischemic stroke (in accordance with the "Chinese Guidelines for Diagnosis and Treatment of Acute Ischemic Stroke 2023," including TOAST etiological/pathogenic subtypes: large-artery atherosclerosis (LAA), cardioembolism (CE), small-artery occlusion (SAO), stroke of other determined etiology (SOE), and stroke of undetermined etiology (SUE)).
Acute onset, with symptoms occurring within 72 hours and being the first episode.
Voluntary participation with signed informed consent.

(2) Inclusion Criteria for Healthy Controls: 1) Healthy control population matched for age, gender, and risk factors (including personal and family history).

Exclusion Criteria

(1) Exclusion Criteria for Healthy Controls:

Patients with cerebrovascular diseases occurring within 72 hours.
Pregnant or lactating patients.

(2) Exclusion Criteria for Acute Ischemic Stroke Patients:

Other types of stroke, including hemorrhagic stroke, mixed stroke, and tumor-related stroke patients.
Patients with coagulation disorders or other hematologic diseases.
Patients with severe cardiovascular, pulmonary, or hepatic diseases.
Renal dysfunction.
Cancer patients.
Patients with active gastric ulcers or gastric bleeding.
Pregnant or lactating patients.

Treatment and study plan

Usually, all enrolled patients with acute ischemic stroke will receive routine medication and/or surgical treatment according to clinical diagnosis and treatment protocols.

Combination Product

The conventional drug therapy includes anticoagulant, antiplatelet, antihypertensive and other drugs. The surgical therapy includes AIS intravenous thrombolysis or endovascular therapy.

Primary outcomes

Evaluate the recurrence, death, and bleeding events of stroke in the research subjects

Time frame: Follow up will be conducted at 3 months, 6 months, and 12 months after the patient's discharge, and the main outcome events mentioned above will be evaluated.

Including recurrent ischemic stroke events; Death events include hemorrhagic death, vascular death, and acute myocardial infarction events; Intracranial or other bleeding events (refer to the International Classification of Bleeding Events ICD-10 code).

Study contacts

Contact information is provided by the study sponsor or research team.

Xia Zhang, PhD

CONTACT

[email protected]

8618120175562

Sponsors and collaborators

Lead sponsor

Peking University Aerospace Center Hospital

Other

Registry information

Official study title

Study Protocol on the Correlation and Mechanistic Study of GGCX Gene With Prognosis in Acute Ischemic Stroke

Important dates

Study start: 2026
Primary completion: 2026
Study completion: 2028
First posted: Dec 8, 2025
Registry last updated: Dec 8, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting